
|Videos|August 16, 2017
Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Author(s)Contagion Editorial Staff
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
Advertisement
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
How New “Shared Clinical Decision Making” Vaccine Category Will Likely Increase Children’s Disease
2
The Potential Ramifications of Changing the MMR Vaccine Into 3 Separate Immunizations
3
Cascading Effects of Executive Order on Childhood Vaccines
4
FDA Accepts NDA for Lonafarnib to Treat Chronic Hepatitis D
5



























































































































































